(PharmaNewsWire.Com, November 07, 2019 ) Factors driving the growth of Microbial Identification Market include heavy burden of infectious diseases coupled with epidemic and pandemic outbreaks, rising food safety concerns, technological developments in microbial identification techniques, and growing government initiatives and funding supporting microbial identification.
Market Size
The global Microbial Identification Market is expected to reach USD 3.00 Billion by 2022 from USD 2.18 Billion in 2017, at a CAGR of 6.6%. To know about the assumptions considered for the study download the pdf brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=10702182
“Instruments are estimated to account for the largest market share in 2017”
On the basis of product and service, the microbial identification market is classified into instruments, consumables, and services. The instruments are expected to lead the global microbial identification market in 2017. Factors driving the growth of this segment include the wide use of instruments across applications and technological advancements, which have led to the launch of innovative products.
“The phenotypic methods segment is estimated to dominate the market in 2017”
By method, the market is segmented into phenotypic, genotypic, and proteomics-based methods. The phenotypic methods segment is anticipated to account for the largest share of the global microbial identification market in 2017. These methods are cost-effective, easy to perform, and can deliver results rapidly.
“By end user, the hospitals, diagnostic laboratories, and blood banks segment is estimated to command for the largest share of the market during the forecast period”
On the basis of end user, the microbial identification market is categorized into hospitals, diagnostic laboratories, and blood banks; food manufacturing companies; beverage manufacturing companies; pharmaceutical companies and CROs; and other end users.
Recent Developments • In 2016, the Becton, Dickinson and Company (US) launched the BD Phoenix M50 ID/AST system to identify bacteria and detect antimicrobial resistance. • In 2017, the Thermo Fisher Scientific Inc. (US) partnered with SpeeDx Pty. Ltd. (Australia) with a view to introduce diagnostic tests in the US market.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
